Australia · Delayed Price · Currency is AUD Botanix Pharmaceuticals Company Description
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States.
The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older.
It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus.
The company was incorporated in 1984 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 1984 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Howie McKibbon |
Contact Details
Address: Tower 5, Collins Square Melbourne, VIC 3008 Australia | |
| Phone | 61 8 6555 2945 |
| Website | botanixpharma.com |
Stock Details
| Ticker Symbol | BOT |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000BOT2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Howie McKibbon | Chief Executive Officer |
| Vincent P. Ippolito | MD and Executive Chairman |
| Graeme Morissey | Chief Financial Officer |
| Chris Lesovitz | Chief Financial Officer of United States of America |
| Paul Seaback | Chief Operating Officer |
| Dr. Boris Meyerson Ph.D. | Chief Business Officer |
| David Morgan | Head of Corporate Affairs |
| Kevin Wojciechowski | Head of HCP Marketing and Sales Training |
| Andrew Bickley | Joint Company Secretary |
| Darin Van Arsdale | Director of Sales Operations |